Clinical Efficacy of Mai Xue Kang Capsules in the Treatment of Acute Ischemic Stroke
Objective To observe the effect of Mai Xue Kang capsules in the treatment of acute ischemic stroke(AIS)and its impact on neurological function and coagulation-related factors.Methods A total of 90 AIS patients admitted to the Department of Neurology at Hemei General Hospital(Hebi Second People's Hospital)from November 2021 to May 2023 were randomly divided into a control group and an observation group,with 45 cases in each group.The control group was treated with aspirin enteric-coated tablets and clopidogrel bisulfate tablets,while the observation group received additional Mai Xue Kang capsules on top of the control group's treatment.The clinical efficacy and related test results were compared between the two groups.Results The total effective rate of the observation group(88.89%)was higher than that of the control group(71.11%),and the difference was statistically significant(P＜0.05).After 14 days of treatment,the scores of the Barthel Index(BI)and the Fugl-Meyer Assessment(FMA)in the observation group were higher than those in the control group,while the scores of the National Institutes of Health Stroke Scale(NIHSS)and the modified Rankin Scale(MRS)were lower,with statistically significant differences(P＜0.05).After 14 days of treatment,the plasma viscosity,fibrinogen,and low-shear viscosity in the observation group were lower than those in the control group,with statistically significant differences(P＜0.05).After 14 days of treatment,the levels of serum homocysteine(Hcy)and lipoprotein associated phospholipase A2(Lp-PLA2)in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion Mai Xue Kang capsules as an adjuvant treatment for AIS is effective,significantly alleviating neurological dysfunction and improving cerebral circulation and clinical symptoms.
Acute ischemic strokeMai xue kang capsulesAspirin enteric-coated TabletsClopidogrel bisulfate tablets
万方数据
维普
